Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.

Gut microbes·2026
Same author

Correction to: Serum and Urinary Metabolomics Reflect the Early Stages of De Novo Metabolic Syndrome After Liver Transplant: A 2-Center Longitudinal Study.

Clinical and translational gastroenterology·2026
Same author

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
Same author

Clinical and Demographic Determinants of Adherence to Digital Monitoring in Cirrhosis: A Prospective Cohort Analysis.

Research square·2026
Same author

Frailty 1 year after liver transplant is associated with long-term mortality: From the Functional Assessment in Liver Transplantation (FrAILT) Study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

The Liver Frailty Index improves mortality risk prediction for GEMA-Na.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

Related Experiment Video

Updated: May 9, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Steroid use in acute liver failure.

Jamuna Karkhanis1, Elizabeth C Verna, Matthew S Chang

  • 1Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY.

Hepatology (Baltimore, Md.)
|August 10, 2013
PubMed
Summary

Corticosteroids did not improve survival in acute liver failure (ALF) patients, and may harm those with severe illness. This finding impacts treatment decisions for autoimmune, drug-induced, and indeterminate ALF.

More Related Videos

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice
11:24

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice

Published on: February 10, 2018

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Related Experiment Videos

Last Updated: May 9, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice
11:24

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice

Published on: February 10, 2018

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Immunology

Background:

  • Acute liver failure (ALF) can present with autoimmune-like features.
  • Corticosteroid therapy is sometimes used for ALF, but its efficacy is debated.

Purpose of the Study:

  • To evaluate if corticosteroids improve survival in autoimmune, drug-induced, or indeterminate ALF.
  • To determine if corticosteroid benefits vary by illness severity.

Main Methods:

  • Retrospective analysis of 361 ALF patients (1998-2007).
  • Comparison of overall and spontaneous survival (SS) between steroid and non-steroid groups.
  • Multivariate analysis controlling for clinical factors.

Main Results:

  • Steroid use did not improve overall survival in ALF patients (61% vs. 66%, P=0.41).
  • Steroid use was associated with diminished survival in patients with the highest Model for Endstage Liver Disease (MELD) scores (>40).
  • Steroid use showed a marginal, non-persistent benefit in spontaneous survival (SS).

Conclusions:

  • Corticosteroids did not enhance overall survival or SS in ALF across all etiological categories.
  • Steroid administration was linked to poorer survival outcomes in ALF patients with high MELD scores.
  • Factors like age, coma grade, MELD, and pH significantly predicted mortality in ALF.